<DOC>
	<DOCNO>NCT00160524</DOCNO>
	<brief_summary>An open-label follow-on safety study CDP870 ( 400 mg every 4 week ) patient Crohn 's Disease complete 26-week blind study ( CDP870-031 [ NCT00152490 ] CDP870-032 [ NCT00152425 ] ) .</brief_summary>
	<brief_title>A follow-on Safety Study CDP870 Subjects With Crohn 's Disease ( CD ) Who Have Completed 26-week Double Blind Study CDP870-031 NCT00152490 CDP870-032 NCT00152425</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Participation either CDP870031 [ NCT00152490 ] CDP870032 [ NCT00152425 ] clinical study subject complete trial Week 26 . Subjects may receive active placebo treatment prior study Subjects must able understand information provide give write informed consent Any exclusion criterion would prevent subject 's participation qualify pivotal study CDP870031 [ NCT00152490 ] CDP870032 [ NCT00152425 ] , although criterion exclude previous participation clinical trial Certolizumab Pegol apply . In addition limit Clinical Disease Activity Index ( CDAI ) score entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>Cimzia</keyword>
	<keyword>CDP870</keyword>
	<keyword>CZP</keyword>
</DOC>